Compare General Dynamics Corporation (GD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs BIO-TECHNE Corp — how do they compare? General Dynamics Corporation trades at $331.32 (market cap $89.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: General Dynamics Corporation is far larger — about 7.9× BIO-TECHNE Corp's market cap, and General Dynamics Corporation pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and BIO-TECHNE Corp for 63 Days on average.
| GD | TECH | |
|---|---|---|
Market Cap | $89.26B | $11.36B |
Volume | 1,496,273 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $395.97 | $72.61 |
52-Week Low | $312.53 | $43.31 |
Typical Hold Time | 85 Days | 63 Days |
Enterprise Value | $94.40B | $11.39B |
Dividend Yield | 1.93% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, supported by robust Pentagon spending and dividend reliability. Technical indicators show oversold conditions with RSI at 11.03, though moving averages signal bearish momentum.
GD presents a compelling value opportunity with attractive valuation metrics (P/E 19.92) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend stability provide downside protection. The stock offers 28% upside to consensus targets with defensive characteristics suitable for long-term investors.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
